Skip to main content
Premium Trial:

Request an Annual Quote

Barry Greene, John Maraganore, Lynne Parshall, David Haen, Ed Umali

Premium
Alnylam Pharmaceuticals said last week that COO Barry Greene will now serve as the company’s president. He will continue to serve as COO.
 
As president, Greene replaces John Maraganore, who will remain the company’s CEO.
 
Greene joined Alnylam in 2003, and will assume responsibility for the company’s business, corporate, and commercial development activities in his new role as president.
 

 
Isis Pharmaceuticals said last week that it has promoted Director and CFO Lynne Parshall to COO.
 
Parshall, who retains her position as CFO and director, joined Isis in 1991.
 

 
CytRx said this week that it has promoted David Haen to the position of vice president of business development. He was previously director of business development at the company.
 
CytRx also said that it has promoted Ed Umali, the company’s director of operations, to the role of vice president of operations.
 
Before joining CytRx, both Haen and Umali were investment bankers, according to the company.
 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.